Rating agencies Moody’s and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries. This action follows Sun Pharma’s proposed acquisition of US-based Organon & Co. The deal is expected to significantly bolster Sun Pharma’s business position and revenue base. Organon will contribute substantially to the group’s earnings after the acquisition. This strategic move will enhance Sun Pharma’s scale and geographic reach.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.